Mark Flory, Ph.D.

  • Scientist, CEDAR, OHSU Knight Cancer Institute, School of Medicine


Mark Flory strives to effectively leverage proteomic technologies to facilitate various research efforts focused on the discovery and validation of early detection biomarkers for multiple cancer indications. He received his Ph.D. in molecular and cellular biology at the University of Washington and subsequently enjoyed postdoctoral training in biological mass spectrometry as a member of Ruedi Aebersold’s group at the Seattle Institute for Systems Biology.  Flory draws on his diverse experiences in applying proteomics in academia, the biotech sector, and at the Stanford University Canary Center for Cancer Early Detection in helping colleagues most effectively apply proteomic methods to augment a variety of early detection studies.



  • {{[0].value }}